Celsion Corporation (NASDAQ:CLSN) Up 11.57%, Delcath Systems, Inc. (NASDAQ:DCTH) Rallying and Up 5.65%
Northern, WI 05/07/2013 (GDPInsider) – Celsion Corporation (NASDAQ:CLSN) has a had a strong start to the day’s trading and is up a lively 11.57%. The stock opened at 1.01 and is trading with a range of 0.99 and 1.11. Volume is strong at 3.98 million shares—nearly double the average volume of 1.35 million. The technical chart has shown a flat line since February but gains have been pushing the price higher and higher in recent sessions. The stock is now 8.76% above its 50-day simple moving average and 19.89% above its 20-day simple moving average.
Celsion has been on the watch list for many analysts and the biotech company has been showing promise with two new drugs which it hopes will help fight liver cancer in patients. One of its bigger candidates is ThermoDox, a liposomal delivery method for moving doxorubicin directly to the site of cancerous tumours. The drug is presently at the Phase III clinical testing phase and many analysts are anticipating the conclusion of the trials. CLSN is trading 42.67% above its 52-week low and 88.67% below its 52-week high. The stock has a target price of 1.70 and a RSI of 64.43—the latter figure presenting an opportunity for gains before the stock reaches overbought territory.
Is CLSN a solid investment at these levels? Get exclusive data and trends here.
Delcath Systems, Inc. (NASDAQ:DCTH) is trading up 5.65% on healthy volume of 2.04 million. The average volume is 3.3 million and the stock has a range of 0.44 and 0.50. At present trading levels DCTH is up 28.18% on its 52-week low of 0.38 and down 82.16% on its 52-week high of 2.73.
Delcath Systems is showing signs of life after a rocky trading session on May 3, 2013 when the stock tumbled 43.86%. The company, it emerged, was under investigation for possible breach of federal securities laws. The storm hasn’t completely blown over but investors look set to try their hands at the stock regardless of the over-hang. DCTH is still down 68.71% on its 50-day simple moving average and down a further 61.84% on its 20-day simple moving average. RSI is deep in oversold territory and stands at 18.86. Analysts have set a target price for the stock at 1.93 and the company has a market cap of $43.54 million.
How Should Investors Trade DCTH Now? Get exclusive insights and updates here.
WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.